Recent Updates
Recently added Catalysts

LTG-305

Phase 1

Undisclosed | Small molecule | Other |Latigo Biotherapeutics, Inc.|Trials Updated: Jul 4, 2025

LTG-305 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Aug 2024

LTG-305 target and mechanism

Molecular targetNa v 1.8
Target classIon Channel
ModalitySmall molecule

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment112

FDA Designations

No designations recorded

LTG-305 clinical trials

LTG-305 · 1 trial · 1 indication

Phase 1 1
NCT06554574A Phase 1 Single and Multiple Ascending Dose Study of LTG-305 Administered Orally in Healthy ParticipantsHealthy
COMPLETED112 Analytics
PHASE1COMPLETED
A Phase 1 Single and Multiple Ascending Dose Study of LTG-305 Administered Orally in Healthy Participants
Healthy
NCT06554574112
Unlock trial analytics

Study Endpoints

Primary Endpoints

To evaluate the safety and tolerability of single and multiple ascending oral doses of LTG-305 in healthy participants.
Up to 7 or 10 days of dosing

Incidence, severity, seriousness, and causality of treatment-emergent adverse events (TEAEs)

To evaluate the pharmacodynamics of LTG-305 in healthy male participants.
0-24 hrs, 1-12 hours

Change from baseline at various individual time points and at various intervals for time to reach PDT and time to reach PTT, for each dose of LTG-305 vs. placebo. Time to reach PDT and time to reach PTT at various individual time points and at various intervals for each dose of LTG-305 vs. placebo. Area above the Curve (AAC) calculated via NPRS scores vs. time, for each dose of LTG-305 vs. placebo Exposure response

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
LTG-305EXPERIMENTAL -
PlaceboPLACEBO_COMPARATOR -

Interventions

NameTypeDescription
LTG-305DRUGPart A: Single-Ascending dose cohorts; Part B: Multiple-ascending dose cohorts
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Male and female participants aged 18 to 55 years, inclusive, at the time of signing the informed consent for SAD and MAD only. For Cold Pressor male participants 18 to 55 years. * Overtly healthy with no clinically relevant abnormalities based on the medical history, physical ...

Countries:New Zealand
Unlock Eligibility Criteria

Explore more on BiopharmaWatch

Latigo Biotherapeutics, Inc. (LTGO)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with LCompanies A to ZEvery biotech and pharma company we track